Answers are grounded in this paper and cite their sources.
This review examines cardiac risks in liver transplant candidates, highlighting implications for management and outcomes.
Liver transplantation (LT) remains the ultimate curative treatment for decompensated cirrhosis and specific hepatobiliary cancers. Adverse cardiac events significantly contribute to post-LT morbidity and mortality, and the prevalence of cardiovascular comorbidities is rising in this new era of steatotic-predominant liver disease. Therefore, successful LT recipient selection requires accurate and timely assessment of pre-LT cardiac risk. This review provides updated data on the prevalence of certain cardiac pathologies in the LT candidate population, examines how these conditions affect waitlist survival and post-LT outcomes, explores advances in screening diagnostics for better cardiac risk stratification, and discusses initial clinical management strategies to mitigate cardiac risk.
No takes yet. Share an insight, caveat, or question.
Dybala et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: